{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-001858","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.560346+00:00","generated_at":"2026-06-20T18:47:21.195951+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aclaris finalizes CEO and CFO employment agreements; Manion $600k base, Balthaser $444k base","bullets":["Douglas Manion appointed CEO effective Jan 1, 2023 with annual base salary of $600,000 and target bonus of 55% of base.","Kevin Balthaser appointed CFO effective Jan 1, 2023 with annual base salary of $444,000 and target bonus of 40% of base.","Both employment agreements have initial two-year term with automatic renewal; severance includes 12-month base salary and COBRA in non-change-of-control terminations.","Under change of control termination, Manion receives additional 6 months salary and 150% target bonus; Balthaser receives additional target bonus; both get full equity acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-001858","json":"https://secwatch.observer/filing/0001104659-23-001858.json","markdown":"https://secwatch.observer/filing/0001104659-23-001858.md","text":"https://secwatch.observer/filing/0001104659-23-001858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/0001104659-23-001858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/tm232381d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:47:21.195951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0e01afcb3","claim":"Douglas Manion was appointed as Chief Executive Officer at Aclaris Therapeutics, Inc..","evidence_excerpt":"appointed Douglas Manion as the Company’s Chief Executive Officer, effective as of January 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/0001104659-23-001858-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c3bc27faae","claim":"Kevin Balthaser was appointed as Chief Financial Officer at Aclaris Therapeutics, Inc..","evidence_excerpt":"appointed Kevin Balthaser as the Company’s Chief Financial Officer, effective as of January 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/0001104659-23-001858-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}